NUVL (NUVL) - Stock Analysis
Last updated: Jun 9, 2026
Closed
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strongest near-term catalyst: reports on 2026-06-08/2026-06-09 said GSK will acquire Nuvalent in an all-cash deal valued around $10.6B, driving a sharp record-level move. Additional support comes from FDA Priority Review acceptance for neladalkib.
Loading chart data...
Idea window: 6/9/2026 – 6/16/2026Sector:
AI Analyst Overview
Loading AI Analyst data...
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 9 | Jun 16 | NUVL | NUVL | Strongest near-term catalyst: reports on 2026-06-08/2026-06-09 said GSK will acquire Nuvalent in an all-cash deal valued around $10.6B, driving a sharp record-level move. Additional support comes from FDA Priority Review acceptance for neladalkib. | Closed | +0.1% |